CANCER AND LEUKEMIA GROUP B

描述(改编自申请者的摘要)：杜克医疗中心是 目前正在完成其作为癌症成员的第二个五年赠款周期 白血病B组(CALGB)。在杜克参与CALGB的整个过程中， 这所大学一直是 总体患者收益，特别是一直是领先的 患者中的机构从主要成员机构中应计。超过了 在上一个赠款周期期间，杜克大学制定了一个附属计划 通过杜克肿瘤联盟(DOC)，该联盟涉及癌症中心和 遍布美国东南部的医院。此附属会员资格 网站数量和临床参与程度仍在不断增长 审判。此外，杜克大学肿瘤学外展服务(DOORS)网络 在邻近地区的小医院和诊所提供现场癌症护理 各县。参与临床试验的院内和院外均为 通过杜克大学集中的临床试验办公室进行协调。这 包括核心管理职能、临床试验的人员支持 疾病和特定模式的临床研究提供的协调 护士，以及由专门的CALGB数据管理员进行的数据管理和跟踪。 这种组织结构通过密切的互动进一步得到加强 与CALGB生物统计和数据管理中心合作 斯蒂芬·乔治博士，他也是公爵的生物统计学主任 癌症中心，从科学上讲，杜克大学在所有 与疾病和模式相关的CALGB委员会。杜克大学的调查人员担任 AML，IV期乳腺癌第三阶段试验研究主席 国家重点开展的骨髓移植佐剂试验 乳腺癌患者的治疗(9082)，以及许多第二阶段 学习。杜克大学也是第一阶段研究中心 药理学/实验治疗学。这一点得到了进一步加强 通过招募迈克尔·科尔文博士担任癌症主任 中心。此外，老龄化中心主任哈维·J·科恩博士 成为CALGB的活跃成员，并在成立和 一个评估癌症和老龄化的工作组的领导。招聘 大卫·哈波尔医生的胸部手术，导致杜克大学成为一个主要的网站 参加CALGB外科试验。多模式支持还包括 由外科其他成员的积极参与提供 肿瘤学以及放射肿瘤学、病理学和相关科学。 杜克大学调查员在CALGB内部在下一笔拨款中的扩展领域 周期将特别针对多模式试验，第一阶段 研究，骨髓移植试验，以及继续参与 正在进行的第二阶段和第三阶段试验。此外，我们还参与了 针对少数群体问题、老年肿瘤学和癌症的社区试验 随着芭芭拉·里默博士和戴夫博士的参与，控制权将扩大。 科琳·麦克布莱德。作为CALGB活动的领先机构，在过去的 十年来，杜克大学期待着为我们的 患者收益和科学参与度的当前和预期水平 在下一个赠款周期的CALGB试验中。

DESCRIPTION (adapted from the applicant's abstract): Duke Medical Center is currently completing its second five year grant cycle as a member of Cancer and Leukemia Group B (CALGB). Throughout Duke's involvement with CALGB, this institution has consistently been one of the top institutions in overall patient accrual and specifically has been one of the leading institutions in patient accrual from a main member institution. Over the period of the last grant cycle, Duke has developed an affiliate program through the Duke Oncology Consortia (DOC) which involves cancer centers and hospitals throughout the Southeast United States. This affiliate membership is still growing in number of sites and level of participation in clinical trials. In addition, the Duke Oncology OutReach Services (DOORS) network provides onsite cancer care at small hospitals and clinics in neighboring counties. Both intramural and extramural clinical trial participation are coordinated through centralized clinical trials offices at Duke. This includes personnel support for core administrative functions, clinical trial coordination provided by disease and modality specific clinical research nurses, and data management and follow-up by dedicated CALGB data managers. This organizational structure is further strengthened by close interaction with the CALGB biostatistics and data management center under the direction of Dr. Stephen George who is also director of biostatistics for the Duke Cancer Center, Scientifically, Duke has active cadre members in all the disease and modality related CALGB committees. Duke investigators serve as study chairs on Phase III trials in AML, stage IV breast cancer, the national high priority trial of bone marrow transplant in the adjuvant treatment of breast cancer patients (9082), as well as numerous Phase II studies. Duke is also a center for Phase I studies for pharmacology/experimental therapeutics. This has been further strengthened by the recruitment of Dr. Michael Colvin to become Director of the Cancer Center. Furthermore, Dr. Harvey J. Cohen, Director of the Aging Center has become an active member of CALGB and was instrumental in the formation and leadership of a working group evaluating cancer and aging. The recruitment of Dr. David Harpole in Thoracic Surgery, led to Duke becoming a major site for participation in CALGB surgical trials. Multimodality support has also been provided by active participation from other members of surgical oncology as well as radiation oncology, pathology, and correlative sciences. Areas of expansion by Duke investigators within CALGB over the next grant cycle will be particularly targeted to multimodality trials, Phase I studies, bone marrow transplant trials, and the continued participation in ongoing phase II and III trials. In addition, our participation in community trials addressing minority issues, gero-oncology, and cancer control will expand with the participation of Dr. Barbara Rimer and Dr. Colleen McBride. As a leading institution in CALGB activities over the last decade, Duke is looking forward to funding support appropriate to our current and anticipated level of patient accrual and scientific involvement in CALGB trials during the next grant cycle.